Pharmafile Logo
Pharmafocus logo
Advanced Search
trials

AbbVie announces further industry and academic collaborations

April 22, 2016
Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago

AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …

News
biogen_logo

Biogen Q1 profits rise boosted by Tecfidera sales

April 22, 2016
Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …

News
lab

Novartis muscular drug fails in Phase III trials

April 22, 2016
Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …

News
actelion_logo

Actelion ups outlook for 2016, reports Q1 net income up 12%

April 22, 2016
Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook

Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …

News
jevtana

A win for Sanofi on Jevtana after NICE reverses guidance

April 22, 2016
Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal

Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …

News
blue_jeans

Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease

April 21, 2016
Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease

Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …

News

PCI Pharma Services’ Ian Parsonage to Share Serialization Expertise at Global Track & Trace Conference

April 21, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ian parsonage, pci pharma, serialisation

Ian Parsonage, Senior Director of Global Serialization for leading pharmaceutical services provider PCI Pharma Services, will present at the Global …

News
Press release
figures_charts

Shares plunge at Sarepta after negative FDA review on muscle disorder drug

April 21, 2016
Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta

Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …

News
gwpharma

GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA

April 21, 2016
Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy

GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …

News
afinitor_combo-front

Novartis drug Afinitor significantly reduces seizures in TSC patients

April 21, 2016
Research and Development Afinitor, Novartis, Tuberous Sclerosis Complex, drug, seizure, seizures, tsc

Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …

News
clinicaltrial1

BioMarin announces positive data from early stage trials of haemophilia A gene therapy

April 21, 2016
Research and Development BioMarin Pharmaceutical, Phase II, drug trial, haemophilia A gene therapy

BioMarin Pharmaceutical (Nasdaq: BMRN) said early-stage trials for its haemophilia A gene therapy showed encouraging data. Chief Medical Officer, Hank …

News
amgen_flag

Amgen’s drug reduces rates of bleeding in rare childhood disorder

April 21, 2016
Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim

Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …

News
novartis_side_building

Novartis Q1 earnings drop as cancer drug sales falter

April 21, 2016
Business Services, Sales and Marketing Financial, Novartis, earnings, first quarter, results

Swiss drugmaker Novartis (SIX: NOVN) on Thursday reported a 13% drop in net income for the first quarter on the …

News
abbvie_0

Abbvie acquires immune-oncology target from argenx

April 21, 2016
Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive

AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …

News

Illumina shares plunge as it cuts Q1 outlook

April 20, 2016
Research and Development, Sales and Marketing Financial, Illumina, Share price, Shares, outlook, revenue, stock market

Shares in Illumina (Nasdaq: ILMN) plunged after the company cut its revenue estimates for the first quarter based on low …

News
opdivo_1_1

Focus: Bristol-Myers Squibb’s wonder drug – Opdivo

April 20, 2016
Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales

By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …

Feature
jardiance-web

Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure

April 20, 2016
Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly

Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …

News
bi_microparts_image

Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business

April 20, 2016
Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, FY, earnings, forecasts, outlook, results

Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees …

News
gilead-sciences

Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies

April 20, 2016
Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir

Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …

News
jj_sign_on_wall

J&J raises FY outlook, Q1 beats estimates

April 20, 2016
Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales

Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …

News
The Gateway to Local Adoption Series

Latest content

Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

April 2, 2026

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026